US-based clinical stage bio-pharmaceutical company Rgenix has begun its Phase Ia/b study of RGX-104 to treat advanced solid malignancies and lymphoma.

RGX-104 is an orally administered, bioavailable, small molecule immunotherapy developed to target the liver X receptors (LXR) to activate expression of the ApoE protein.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

It affects both myeloid-derived suppressor cells (MDSCs), as well as tumour blood vessels. MDSCs are known to inhibit T-cells and other immune system cells from attacking tumours.

The study will be divided into an initial dose-escalation stage, which will determine the pharmacokinetic, pharmacodynamic, biomarker and safety of an optimal biological dose RGX-104 while treating patients with advanced solid malignancies and lymphoma.

"RGX-104 represents the first LXR-ApoE targeting drug in clinical development for cancer."

The expansion stage of the study will assess the preliminary efficacy of RGX-104, while examining patients with at least four types of cancers.

See Also:

Rgenix co-founder and CEO Masoud Tavazoie said: “RGX-104 represents the first LXR-ApoE targeting drug in clinical development for cancer.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“Because of its ability to inhibit tumour growth and metastasis as a single agent in drug-resistant cancer types via a novel mechanism, RGX-104 has the potential to transform the treatment landscape for several common cancer types, addressing urgent unmet needs in oncology.”

RGX-104 has demonstrated efficacy in reversing the immunosuppressive and pro-angiogenic effects of cancers by activating ApoE expression in cancer and highly specific circulating immune cells, which finally leads to killing these cells and blood vessels within the tumour microenvironment.